drugset / Trial / NCT00224055

Effect of Ferrlecit® Versus Oral Iron on Iron Deficient Chronic Kidney Disease (CKD) Patients

NCT00224055

Phase 4 Completed 89 enrolled Watson Pharmaceuticals
RandomizedParallel-groupOpen-labelTreatment

Summary

This study compares the effect of Ferrlecit® (a form of intravenous iron) to ferrous sulfate (a form of oral iron) in treating anemia and iron deficiency in chronic kidney disease patients who are not receiving erythropoietic agents (hormones that stimulate the bone marrow to make more red blood cells).

Timeline

Start
2003-04
Primary completion
2004-09
Completion
2004-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ferrous Sulfate Diagnostic / imaging agent 325 mg Oral
Subject Sodium Ferric Gluconate Complex Unknown 250 mg Intravenous